search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Effectiveness of probiotics of children with chronic abdominal pain en bacterial overgrowth.


- candidate number11130
- NTR NumberNTR3285
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR14-feb-2012
- Secondary IDsNL39061.028.11  METOPP Tilburg
- Public TitleEffectiveness of probiotics of children with chronic abdominal pain en bacterial overgrowth.
- Scientific TitleEffectiveness of probiotics in the treatment of children with chronic abdominal pain and small intestinal bacterial overgrowth. A double blind placebo-controlled randomized study.
- ACRONYMSIBO study
- hypothesisChildren with chronical abdominal pain and small intestinal bacterial overgrowth supplemented with probiotics will show less abdominal pain compared to placebo.
- Healt Condition(s) or Problem(s) studiedChronic abdominal pain, Small intestinal bacterial overgrowth, Children, Functional abdominal pain
- Inclusion criteriaChildren aged 8-18 years are included if they meet the criteria for functional dyspepsia, IBS, functional abdominal pain (FAP) or abdominal migraine, based on the Rome III Criteria for Functional Bowel Disorders Associated with Abdominal Pain or Discomfort in Children and have small intestinal bacterial overgrowth, diagnosed on hydrogen breath test as a fasting breath hydrogen concentration > 20 ppm or an increase of H2 levels of > 12 p.p.m. over the baseline value after ingestion of glucose.
- Exclusion criteria1. Children with abdominal pain as result of inflammatory, anatomic, metabolic or neoplastic disease;
2. Children who were prescribed antibiotics or probiotics in the last month;
3. Children who are critically ill or admitted at the ICU. Children who receive feeding via a tube.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-mrt-2012
- planned closingdate1-mrt-2014
- Target number of participants70
- InterventionsThe probiotics consist of a mixture of Bifidobacterium and Lactobacillus (8 grams of powder 4 x 10E9 cfu Bifidobacterium and Lactobacillus (Ecologic junior)). This has te be used once a day for 8 weeks.
The control group will receive a placebo (Placebo is a composition of rice starch, maltodextrins and vegetable protein, and contains no bacterial strains).
- Primary outcomeThe reduction of abdominale pain is our primairy outcome. Abdominale pain is measured by an abdominal pain diary. Patients will be instructed to score pain intensity and pain frequency during 1 month at baseline period, after finishing the treatment and at 6 and 12 months follow up. Clinical remission is defined as a decrease of the pain intensity score and pain frequency score of > 80%; significant improvement is defined as a decrease of pain intensity score and pain frequency score between 30% and 80% and treatment is considered unsuccessful if the scores improved < 30% or got worse.
- Secondary outcomeSecondary outcome measures is the presence of small intestinal bacterial overgrowth.
- TimepointsOutcomes are assessed at:
t=0: baseline; before randomisation;
t=1: directly after finishing the treatment period;
t=2: six months follow up;
t=3: twelve months follow up.
- Trial web siteN/A
- statusstopped
- CONTACT FOR PUBLIC QUERIESDrs. J.J. Korterink
- CONTACT for SCIENTIFIC QUERIESDr. J.M. Deckers-Kocken
- Sponsor/Initiator Jeroen Bosch Hospital
- Funding
(Source(s) of Monetary or Material Support)
Winclove Bio Industries B.V., Orthica, Almere
- PublicationsN/A
- Brief summaryBackground: Chronic abdominal pain is a common problem of school-going children and is one of the most frequent reasons to visit a pediatrician. Pathogenesis remains unclear. Recent studies have pointed to an underlying gut microbial mechanism for chronic abdominal pain. When the microbial population native to the large intestine migrates proximally into the small intestine, a shift in the host-gut microbial relationship occurs, known as small intestinal bacterial overgrowth (SIBO). Similar to children with chronic abdominal pain, children with SIBO complain of nausea, abdominal pain, flatulence, diarrhoea and constipation. Scarpellini et al. showed an association between small intestine bacterial overgrowth and irritable bowel syndrome in children. Therapeutic options are limited. Recent study results showed that 70% of children with chronic abdominal pain and small intestinal bacterial overgrowth have an improvement of symptoms after treatment with probiotics. Although these data are promising, the study group was small and it missed a control group.
Aim: The aim of this study is to compare the effect of probiotics on chronic abdominal pain and small intestinal bacterial overgrowth compared to placebo.
Methods: 70 children, aged between 8-18yrs, with chronic abdominal pain and bacterial overgrowth will be randomized to one of these treatments: probiotics or placebo. Primary outcome measures are the percentages of patients with complete remission of chronic abdominal pain after the treatment phase and at six and twelve months follow up. Secondary outcome measures is the presence of small intestinal bacterial overgrowth.
- Main changes (audit trail)
- RECORD14-feb-2012 - 6-dec-2013


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl